Skip to Main Content

Paper Details

Evaluation of Berberine as an Adjunct to TB Treatment.
Front Immunol
8
2021
Berberine, C57BL, CD11b+, CD11b+ dendritic cell, COVID-19, Mtb, TB, Tuberculosis, axenic cultures, berberine, communicable disease, derived macrophages, human, human monocyte, human monocyte-, interstitial macrophage, isoniazid, mice, mouse, murine, neutrophil, neutrophils, primary murine bone marrow-derived macrophages, pulmonary TB, rifampicin
Author NameAffiliation
Reto GulerInternational Centre for Genetic Engineering and Biotechnology (ICGEB)
Reto GulerDivision of Immunology and South African Medical Research Council (SAMRC) Immunology of Infectious Diseases, Institute of Infectious Diseases and Molecular Medicine (IDM), University of Cape Town
Reto GulerWellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa) and Institute of Infectious Diseases and Molecular Medicine (IDM), University of Cape Town
Harukazu SuzukiRIKEN Center for Integrative Medical Sciences
Harukazu SuzukiRIKEN Center for Integrative Medical Sciences
Frank BrombacherInternational Centre for Genetic Engineering and Biotechnology (ICGEB)
Frank BrombacherDivision of Immunology and South African Medical Research Council (SAMRC) Immunology of Infectious Diseases, Institute of Infectious Diseases and Molecular Medicine (IDM), University of Cape Town
Frank BrombacherWellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa) and Institute of Infectious Diseases and Molecular Medicine (IDM), University of Cape Town
  • 1 - 8

Datasets

Release 1.2